The anticoagulants market value is projected to exceed $80B by 2030, according to a report by Global Market Insights Inc.
Regions such as Europe and North America are witnessing a notable spike in the elderly population. According to Statistics Canada, the share of people aged 65 years and above is one of the fastest growing age groups in the country, with the numbers rising by 18.3% between 2016 and 2021. These numbers indicate an increase in the burden of various diseases, such as deep vein thrombosis, stroke, heart attacks, and coronary artery diseases (CAD).
Anticoagulants market from the warfarin (vitamin K antagonist) segment is estimated to register more than 7% CAGR through 2030. Increase in the number of obese patients owing to unhealthy lifestyle choices will boost the demand for these drugs. Many reputed manufacturers are introducing advanced versions of warfarin that are produced with technologies to enhance their performance. The drugs not only treat various diseases, but also give patients several treatment options.